Mavyret is commonly used to help with the management of Chronic Hepatitis C Virus (HCV) infection in adults and pediatric patients aged 3 years and older. The primary goal is the management of the active viral presence, which may assist with achieving a Sustained Virologic Response (SVR).

This medication is generally applied in addressing the fundamental condition of chronic HCV infection across all major genetic types (Genotypes 1, 2, 3, 4, 5, and 6). It is considered relevant for patients across conditions where functional stability becomes affected by HCV, ranging from those with no liver scarring to those with compensated cirrhosis (Child-Pugh A).

In complex clinical settings, the treatment is often used during phases when additional symptomatic support is needed for patients with severe kidney impairment, including those on dialysis, those who are co-infected with HIV-1, or individuals who experienced prior Direct-Acting Antiviral (DAA) treatment failure. This provides support that helps ease the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

“Mavyret is applied across domains where additional symptomatic support is needed to manage the condition marked by increased physiological stress.”

Quick Fact: Supports the management of HCV-Related Symptoms

---

Mavyret (glecaprevir and pibrentasvir) is an FDA-approved prescription medication used to treat chronic Hepatitis C Virus (HCV) infection in adults and children 3 years of age and older. It is effective against all six major HCV genotypes (1 through 6).

Who Can Use Mavyret?

Patient Group	Conditions/Notes
Adults and Children (3 years old)	With chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection.
Patients with HIV-1 Coinfection	Can be used, but close monitoring for drug-drug interactions is required.
Patients with Mild (Child-Pugh A) or Moderate (Child-Pugh B) Liver Impairment	Treatment duration may vary based on prior treatment and genotype.

---

Who Cannot Use Mavyret?

Mavyret is contraindicated and should not be used in patients with:

• Severe Liver Impairment (Child-Pugh C): Due to the risk of worsening liver function.
• A history of decompensated cirrhosis: Advanced liver disease.
• Patients taking certain medications: Specifically, those containing atazanavir (a protease inhibitor for HIV) or rifampin (an antibiotic), due to significant drug-drug interactions that can lead to increased Mavyret levels or reduced effectiveness.
• Known hypersensitivity (allergic reaction) to glecaprevir or pibrentasvir, or any of the inactive ingredients.

Interactions with other medicines and products

Mavyret (glecaprevir and pibrentasvir) has documented interactions with several categories of medicinal products, primarily due to its strong ability to inhibit drug transporters. Specifically, glecaprevir and pibrentasvir are inhibitors of the P-glycoprotein (P-gp), BCRP, and OATP1B1/3 transporters, which can significantly increase the exposure of co-administered medicines that are substrates of these transporters.

Contraindicated Combinations

Co-administration is strictly contraindicated with the following products:

• Statins such as Atorvastatin and Simvastatin
• Rifampin (an anti-tuberculosis medicine)
• Atazanavir (an HIV medicine)
• Dabigatran etexilate (an oral direct thrombin inhibitor)
• Products containing Ethinyl Estradiol (e.g., combined oral contraceptives)

Other Significant Interactions

Interactions may also occur with strong CYP3A inducers and certain other medicines:

• Not Recommended: Co-administration with strong CYP3A inducers like Carbamazepine, Efavirenz, or the herbal product St. John's Wort is not recommended, as it may reduce Mavyret's effectiveness.
• Dose Modification Required: Dose adjustment or monitoring is necessary for medicines such as Digoxin and certain other Statins (e.g., Rosuvastatin, Pravastatin) to manage increased exposure.

Administration Requirements

Mavyret must be taken with food to ensure adequate systemic drug exposure and efficacy.

Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination that executes a dual-mechanism strategy to directly interfere with the Hepatitis C Virus (HCV) life cycle . Its mechanism is focused exclusively on two essential, non-host viral proteins.

Glecaprevir acts as an inhibitor of the viral NS3/4A protease enzyme. This enzyme is required to cleave the large, precursor viral polyprotein into mature, functional non-structural proteins. By blocking this post-translational processing step, the drug blocks the manufacturing of essential viral machinery, influencing the shutdown of viral proliferation within the host cell.

Pibrentasvir targets the multifunctional NS5A protein, disrupting subsequent steps of the viral life cycle. NS5A is critical for both the replication of viral RNA and the assembly of new infectious particles (virions). By blocking this protein, the drug stops the copying of genetic material and prevents the packaging of viral components.

The resulting synergistic dual blockade attacks two non-overlapping viral pathways, which influences the development of viral resistance. The physiological effect is the cessation of active viral proliferation and a reduction in circulating viral load.

Administration Guidelines: How to Use Mavyret

Mavyret is an antiviral medication administered orally and must be taken once daily with food. The total daily dose for most adults, adolescents 12 years of age and older, or children weighing at least 45 kg is three tablets taken at the same time.

Administration Method and Preparation

• Tablets (for patients 12 years old or 45 kg): Swallow the tablets whole. Do not chew, crush, or break the tablets, as this may alter the drug's absorption.
• Oral Pellets (for children 3 to less than 12 years old, or < 45 kg): A weight-based dose of oral pellets is used for younger children. The pellets must be mixed with a small amount of soft food or an acidic drink and swallowed without chewing. The entire dose must be consumed within 30 minutes of preparation, and any unused portion of the mixture must be discarded.

Treatment Duration and Missed Doses

The total treatment duration (e.g., 8, 12, or 16 weeks) is fixed and depends on the patient's viral genotype and prior treatment history, as determined by a healthcare provider. It is essential to complete the entire course of treatment.

• If a dose is missed by less than 18 hours: Take the missed dose with food as soon as possible, and then take the next dose at the regularly scheduled time.
• If a dose is missed by 18 hours or more: Do not take the missed dose. Simply take the next dose at the usual scheduled time. Do not take a double dose to make up for a missed one.

Overview of Clinical Trials

Mavyret is a fixed-dose combination of two direct-acting antiviral agents, glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor). Clinical evidence primarily stems from a large program of Phase 2 and 3 studies (e.g., SURVEYOR, ENDURANCE, and EXPEDITION trials) that evaluated its use in chronic Hepatitis C Virus (HCV) infection across all six major genotypes (GT1–6).

Key trial endpoints focused on achieving Sustained Virologic Response (SVR12), defined as the absence of detectable HCV RNA 12 weeks after the end of treatment. This outcome is generally regarded as a marker of viral clearance.

---

Efficacy and Treatment Duration

Clinical studies assessed Mavyret across various patient populations, including those who were treatment-naïve (untreated) and those with specific treatment challenges, such as chronic kidney disease (CKD) or compensated cirrhosis. Efficacy data showed high rates of SVR12 across all genotypes when the drug was used according to the recommended duration, often in as little as 8 weeks for treatment-naïve patients without cirrhosis or with compensated cirrhosis.

Patient Population	Recommended Duration (Weeks)
Treatment-Naïve, No Cirrhosis	8
Treatment-Naïve, Compensated Cirrhosis	8
Select Treatment-Experienced Patients	12 or 16

---

Safety and Tolerability

Across multiple clinical trials involving over 2,300 adults, the most frequently reported adverse reactions were headache and fatigue. These reactions were typically mild in severity. Patients with moderate or severe liver impairment (Child-Pugh B or C) were excluded from treatment due to potential risks of hepatic decompensation. Prior to treatment initiation, testing for Hepatitis B Virus (HBV) infection is required due to the risk of HBV reactivation in co-infected patients.

Common questions about Mavyret (FAQ)

Q: How quickly does Mavyret start to clear the Hepatitis C virus?

A: Mavyret is designed to start inhibiting the virus immediately after administration by blocking its replication. Studies show a rapid reduction in the amount of Hepatitis C Virus (HCV) RNA, which is a key measure of viral presence, often within the initial few weeks of treatment. The final goal of treatment (viral clearance) is officially measured 12 weeks after the course is completed.

Q: Can I drink alcohol at all during the Mavyret treatment period?

A: Regulatory documents do not specifically list an interaction between Mavyret and alcohol. However, official health authorities and liver specialists emphasize that avoiding alcohol is crucial for patients with Hepatitis C due to alcohol’s established link to severe liver damage and a more rapid progression of liver disease.

Q: Is it safe to take Mavyret with over-the-counter pain relievers like Tylenol (acetaminophen)?

A: A specific interaction between Mavyret and acetaminophen (Tylenol) is not detailed in the official product labeling. However, because acetaminophen is processed by the liver, the product label indicates that it should be used with caution in people with underlying liver disease. It is important that patients do not exceed the recommended maximum daily dose.

Q: Does Mavyret affect cholesterol levels?

A: Mavyret is known to affect drug transporters (P-gp, BCRP, OATP1B1/3), which can lead to increased exposure of certain co-administered cholesterol-lowering medicines (statins). Due to this mechanism, some statins are contraindicated, and others may require a dose adjustment, according to the regulatory information.

Q: What does SVR (Sustained Virologic Response) mean in relation to Mavyret?

A: Sustained Virologic Response (SVR) is the primary measure of Mavyret's effectiveness in clinical studies. Specifically, SVR12 means the Hepatitis C Virus (HCV) RNA remains undetectable in the blood 12 weeks after the last dose of treatment. Achieving SVR is generally considered a strong marker that the viral infection has been eliminated.

Q: What should I do if my side effects from Mavyret seem to get worse?

A: Official patient counseling information advises contacting a healthcare professional if serious or worsening symptoms occur. This includes any symptoms that could indicate liver problems, such as unusual nausea, sudden fatigue, confusion, or the yellowing of the skin or eyes (jaundice).

Q: What happens in the body when Mavyret is treating the virus?

A: Mavyret is classified as a direct-acting antiviral (DAA) that utilizes two different medicines in one tablet. These medicines are designed to block two essential, non-host viral proteins (NS3/4A protease and NS5A) that the Hepatitis C Virus needs to copy and spread, effectively halting the viral life cycle.

Q: Is it required to take Mavyret at the exact same time every day?

A: Regulatory guidance advises taking Mavyret once daily with food. This practice helps ensure consistent drug levels are maintained in the body throughout the treatment course. Official information also provides specific, time-based instructions for how to handle a missed dose.

Q: Can Mavyret be used to treat Hepatitis B as well?

A: Mavyret is indicated and approved only for the treatment of chronic Hepatitis C Virus (HCV) infection. Due to the risk of Hepatitis B Virus (HBV) reactivation, the product label includes a warning that all patients must be screened for HBV before starting Mavyret.

Q: Does taking Mavyret affect my ability to drive or operate machinery?

A: Official European regulatory information states that Mavyret is not expected to directly impair a person's ability to drive or use machines. However, patients are advised to be aware that the most frequently reported side effects, headache and fatigue, could potentially affect their ability to perform these tasks safely.

Q: Are there different doses of Mavyret depending on the person or virus type?

A: The total daily dose for the tablet formulation is fixed for adults and adolescents weighing at least 45 kg, regardless of the Hepatitis C genotype or severity of renal impairment. The only variation is the use of a weight-based dose with the oral pellet formulation, which is used for younger children.

Q: Are there any specific laboratory tests needed before starting Mavyret?

A: Yes, regulatory documentation mandates that all patients must be tested for evidence of current or prior Hepatitis B Virus (HBV) infection before starting Mavyret treatment. This is a safety measure due to the potential risk of HBV reactivation in co-infected patients.

Mavyret (glecaprevir/pibrentasvir) must be stored under specific conditions mandated by regulatory labeling to maintain its stability and potency.

Storage Requirements

The medicine must be stored at or below 86 F (30 C). The product must be kept in its original package and the container should be kept tightly closed to protect it from excess heat and moisture. The oral pellets formulation, when mixed with food, must be administered immediately, as it becomes less effective if swallowed after 15 minutes, and any leftover mixture must be discarded.

Safety and Disposal

For child safety, Mavyret and all medicines must be kept out of the reach of children, ideally in a secured location. Unused or expired Mavyret should be thrown away safely, with disposal managed according to local regulations and relevant governmental guidelines.